ESPR Q4 2024 Earnings — Esperion Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

ESPREsperion Therapeutics, Inc.

$577M

Q4 2024 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$69M+114.3% YoY

Gross Profit

$43M62.9% margin

Operating Income

-$4M-6.4% margin

Net Income

-$21M-30.8% margin

EPS (Diluted)

$-0.11

QoQ Revenue Growth

+33.9%

Cash Flow

Operating Cash Flow

-$35M

Free Cash Flow

-$35M

Stock-Based Comp.

$3M

Balance Sheet

Total Assets

$344M

Total Liabilities

$733M

Stockholders' Equity

-$389M

Cash & Equivalents

$145M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$69M	$32M	+114.3%
Gross Profit	$43M	$21M	+109.1%
Operating Income	-$4M	-$42M	+89.6%
Net Income	-$21M	-$56M	+62.2%

Revenue Segments

Collaboration Revenue

$83M58%

Product

$60M42%